Background. Silent cerebral small-vessel disease (CSVD) is defined as white matter hyperintensities, silent brain infarction, or microbleeds. CSVD is responsible for future vascular events, cognitive impairment, frailty, and shorter survival. CSVD prevalence among middle-aged people living with well-controlled human immunodeficiency virus (HIV) infection (PLHIV) is unknown.
small subcortical infarcts and prominent perivascular spaces were more recently recognized as CSVD markers [5] . CSVD features probably develop over many years before becoming clinically evident [1] . Although early CSVD could be considered an incidental finding, attributable to a quasi-physiological aging process, when the CSVD burden reaches a certain severity degree, it attests to advanced brain involvement associated with clinical disturbances [1, 2, 6, 7] . WMH Fazekas grade 2/3 is usually accepted as severe, but the severity threshold load of CMBs and/or SBIs is still debated [2, 8, 9] . In most people, these MRI brain damage markers do not occur alone [1, 3] . According to Wardlaw et al [1] , the effect(s) of their combined presence better summarize the cumulative CSVD impact on the brain than each feature alone.
Although the underlying CSVD pathogenesis is most often unknown, age and hypertension are its 2 major risk factors [1, 2] . Recent evidence strongly suggests that CSVD development and progression may result from altered immune homeostasis in the central nervous system, leading to endothelial failure, astrogliosis, and microglial activation, and hence to neurovascular unit dysfunction [10, 11] .
Combination antiretroviral therapy (cART) now ensures viral suppression and immunological recovery in a majority of people living with human immunodeficiency virus (PLHIV), obtaining dramatically improved life expectancy [12] . As a result, ever more PLHIV are reaching 50 years of age and becoming prone to age-related cerebrovascular events [13] .
Some authors evoked a higher CSVD risk among PLHIV during the past decade [14] [15] [16] [17] [18] [19] [20] , but no studies compared the CSVD prevalence between PLHIV with long-term human immunodeficiency virus (HIV) suppression and matched HIV-uninfected controls (HUCs). This cross-sectional study, with prospective enrollment of PLHIV and frequency age-and sex-matched HUCs, was designed to determine whether full-spectrum silent CSVD is more prevalent in middle-aged PLHIV with sustained immunovirological control. Because we wanted to examine the role of HIV infection itself, we selected PLHIV without hepatitis C virus (HCV) infection [19] , past or ongoing neurological diseases (AIDS-defining neurological events [ADEs]), and alcohol or illicit drug abuse.
METHODS

Design of the MicroBREAK Study
The French National Agency for Research on AIDS and Viral Hepatitis (ANRS) EP51 Microvascular Brain Retina and Kidney (MicroBREAK) study (NCT identifier 02082574) is a cross-sectional study with prospective enrollment of PLHIV and frequency age-and sex-matched HUCs. It was designed to estimate MRI-detected CSVD prevalence among PLHIV.
Inclusion criteria for PLHIV were (1) age ≥50 years; (2) HIV diagnosis known for ≥5 years; (3) current CD4 count ≥350 cells/ µL; and (4) sustained plasma HIV load (pVL) <40 copies/mL for ≥12 months on cART. Exclusion criteria were prior/current (1) neurological ADEs (all records were thoroughly reviewed to search for such neurological conditions and/or their treatments); (2) large territorial stroke or transient ischemic attack; (3) HCV infection; (4) alcohol or illicit substance abuse, as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (except for occasional cannabis or popper use, <1 time/ month) [21] ; (5) diabetes mellitus with microvascular complications (ie, estimated glomerular filtration rate [eGFR] <60 mL/ minute, or microalbuminuria/proteinuria >300 mg despite angiotensin-converting enzyme inhibitor use or diabetic retinopathy); (6) uncontrolled hypertension (systolic or diastolic blood pressure of ≥180 or ≥100 mm Hg, respectively); (7) eGFR <15 mL/minute/1.73 m 2 ; and (8) contraindications to MRI. A secondary exclusion criterion was an MRI-revealed covert brain lesion (notably an ADE, posttraumatic lesion, tumor, or large, territorial stroke). The exclusion criteria for HUCs were the same as for PLHIV, without HIV-related parameters. HIV seronegativity was systematically confirmed by enzyme-linked immunosorbent assay or a rapid test.
PLHIV were enrolled in 4 university hospital infectious disease units caring for a total of 14 000 PLHIV. HUCs were voluntarily enrolled through consultations for eyeglasses or MRI other than brain MRI (Fondation Adolphe de Rothschild), or medical check-ups (Institut Médical Montsouris, and general practitioner J.-P. V. 's office), all facilities located in the same Paris neighborhood, or through a response to calls for volunteers posted by Fondation Rothschild.
Ethics Committee Approval
This study was approved by the Comité de Protection des Personnes Île-de-France VI, Groupe Hospitalier Pitié-Salpêtrière Ethics Committee, and adhered to the tenets of the Declaration of Helsinki. Written informed consent was obtained from all participants. No participants were reimbursed or charged for their participation in the study.
Assessments
At enrollment, a clinician recorded the following information during an interview: sociodemographic characteristics, lifestyle behaviors (tobacco, alcohol, and drugs), weight and height, blood pressure, HIV/AIDS history, other past/current neurological conditions, immunological and virological findings, traditional cardiovascular risk factors, and their specific treatments.
Magnetic Resonance Imaging
All MRI examinations were acquired on the same 3T Ingenia scanner (Philips Medical Systems, Best, the Netherlands) with a 16-channel neurovascular coil, using a standardized protocol that included whole-brain with b values at 0, 1000, and 2000. Brain MRI took 10 minutes. CSVD was defined according to the Standards for Reporting Vascular Changes on Neuroimaging Criteria [5] . WMHs of presumed vascular origin were defined as hyperintense signal abnormalities, without cavitation, in white matter on 3D-FLAIR images [5] . Subcortical gray matter or brainstem hyperintensities were also analyzed. WMHs were manually rated from mild to severe according to the revised 3 Fazekas scale severity classes [22] . CMBs were defined as small hypointense lesions on T2* sequences [5] . Small SBIs (3-15 mm in diameter) were defined as hypointense round or ovoid subcortical lesions on FLAIR images, with a signal similar to that of the cerebrospinal fluid cavity in the perforating arteriole territory [5] . Two experienced neuroradiologists (J. S. and P. R.), blinded to clinical and demographic data, analyzed all MRI scans, along with a third neuroradiologist (J.-C. S.) in case of discordance. Concordance between the first 2 readers was 80.2%.
Outcomes
The primary endpoint was full-spectrum CSVD, as defined by the presence of WMHs, SBIs, and/or CMBs. The secondary endpoint was severe CSVD prevalence, defined as Fazekas grade 2/3 WMHs, ≥1 SBIs, and/or ≥1 CMBs, thereby excluding patients with only Fazekas grade 1 WMHs, considered mild.
Statistical Analyses
Categorical variables are expressed as number (percentage), and continuous variables as median (interquartile range). PLHIV and HUC characteristics were compared with χ 2 test for categorical variables and Wilcoxon test for continuous variables. The sample size was calculated to detect a 7.5% difference between the 2 groups' CSVD frequencies. For 80% statistical power, 431 PLHIV and 215 HUCs were needed, that is, a 2:1 ratio.
To assess the prevalence difference between PLHIV and HUCs, we used a logistic regression model adjusted for variables that differed between them, with the modifying effects of all those variables being tested. Other than analytical adjustments, those variables are already known to be linked to CSVD or cardiovascular events in the general population [1] [2] [3] . The same strategy was used for severe CSVD. The population attributable fraction (PAF) was calculated according to Rückinger et al [23] . CSVD-associated factors for PLHIV were identified with logistic regression models. For continuous variables, the decision to treat the variable as a continuous or categorical variable was based on the lowest Akaike information criterion value for the corresponding univariable analysis. Variables achieving P < .15 in univariable analysis were included in the multivariable logistic regression model. Analyses were computed with SAS software version 9.3 (SAS Statistical Institute, Cary, North Carolina) and the Stata software package version 10 (StataCorp, College Station, Texas). All statistical tests were 2-tailed, with α = .05. reply, or failed to come for their scheduled MRI, and 26 PLHIV and 7 HUCs were excluded secondarily, leaving 456 PLHIV and 154 HUCs included in the final analyses. Frequency ageand sex-matching was not completely successful (Table 1) : For PLHIV and HUCs, respectively, the median age was 56 and 58 years (P = .001), among whom 84.9% and 77.3%, respectively, were men (P = .030). PLHIV, compared to HUCs, had more frequent hypertension, hypercholesterolemia (total cholesterol >5.2 mmol/L, low-density lipoprotein cholesterol >4.1 mmol/L, or taking lipid-lowering agents), hypertriglyceridemia (triglycerides >1.7 mmol/L or taking fibrates), excessive alcohol use, and a personal history of cardiovascular disease (ie, myocardial infarction, coronary artery disease, or heart failure), but comparable diabetes and smoking rates. Two-thirds (66.9%) of PLHIV were men who had sex with men (MSM), 62.2% were diagnosed with HIV infection before 1996, 18.9% had history of nonneurological ADEs, and the median nadir and current CD4 counts were 196 cells/μL and 655 cells/μL, respectively. As per the inclusion criteria, all PLHIV had controlled pVL (<40 copies/mL), and none were HCV-infected or illicit drug users.
CSVD was detected in 51.5% of PLHIV and 36.4% of HUCs ( Figure 2) , with WMHs being the most frequent primary CSVD lesion. Severe CSVD was observed in 19.3% of PLHIV and 14.3% of HUCs. Based on the comparisons of PLHIV and HUC characteristics, logistic regression models were adjusted for age, sex, alcohol consumption, hypertension, hypercholesterolemia, hypertriglyceridemia, and a personal history of cardiovascular disease. CSVD was significantly more frequent in PLHIV than HUCs, with an adjusted odds ratio (aOR) of 2.3 (95% confidence interval [CI], 1.5-3.6), but not for severe CSVD (aOR, 1.6 [95% CI, .9-2.7]). When examining the modifying effect of all variables included in the models, only the interaction with age was significant (P = .02; Figure 3 ). The odds of having CSVD increased with age, especially among HUCs. However, compared to HUCs, the odds of having CSVD was much higher for PLHIV <54 years old (aOR, 5.3), lower for PLHIV 54-60 years old (aOR, 3.7), and not significantly different for PLHIV aged >60 years (aOR, 1.0).
To further explore the decreasing relative risk with increasing age among PLHIV, we separately calculated the PAF for subjects aged ≤60 and >60 years. The HIV infection-CSVD association was more evident for subjects aged ≤60 years (HIV PAF, 56%) than for those aged >60 years (HIV PAF = 4%), whereas the cardiovascular risk factor PAF was comparable for the 2 age groups. Table 2 shows the results of univariable and multivariable analyses of risk factors for CSVD in PLHIV. Factors associated with higher odds of having CSVD were non-MSM male sex (aOR, 2.2), with MSM as the reference group; hypertension (aOR, 1.7); older age (aOR, 2.1 at 54-60 years and 4.0 at >60 years); and a CD4 count nadir <200 cells/μL (aOR, 1.5). 
DISCUSSION
The full-spectrum silent CSVD (WMHs, CMBs, and SBIs) prevalence was 51.5% among middle-aged PLHIV diagnosed with HIV infection <20 years ago, cART treated for 17 years, with sustained pVL suppression and immune recovery. The aOR was 2.3 compared to matched HUCs. The strength of the HIV-CSVD association weakened with advancing age. Older age, hypertension, a CD4 count nadir <200 cells/µL, and non-MSM male status were independently associated with a higher risk of CSVD for PLHIV. Previous studies on CSVD in PLHIV were variously hampered by the lack of a matched control group [14, 15, 17, 18] , the large proportion of immunovirologically uncontrolled PLHIV [14, 15, [17] [18] [19] [20] , insufficient data on CD4 cell counts and/or pVL [17, 18] , and potential contributors to CSVD (eg, current cocaine use and HCV coinfection) [14, 15, [17] [18] [19] [20] , and a retrospective design based on brain MRI ordered for various clinical indications [17] . The only other study comparing CSVD in HUCs and PLHIV with sustained pVL suppression was designed to evaluate the impact of WMH on cognition, and not full-spectrum CSVD prevalence [16] . Each CSVD component was assessed separately, and WMH volume and location were reported. However, full-spectrum CSVD is more meaningful because no evidence adequately supports that the primary CSVD lesions are different disorders [1] . Our results represent a first estimation of full-spectrum CSVD prevalence in middle-aged individuals with well-controlled, cART-treated HIV, with the exclusion of other contributory factors. WMH lesion location is being examined in an ongoing subanalysis of WMH volume. The difference between periventricular and deep white-matter WMHs is still being debated, with some authors suggesting that they have different pathogeneses, risk factors, and clinical consequences. Moreover, WMHs coalesce when numerous, making the distinction even more hazardous [1, 5] . Hence, many studies on PLHIV and the general population still include only total WMHs in their analyses. We found that full-spectrum CSVD prevalence grew geometrically with increasing HUC age. This age-related increase was less pronounced for PLHIV. Indeed, the CSVD relative risk was much higher for PLHIV than HUCs <60 years old. Given the cross-sectional nature of our study, this finding could be explained by a competitive risk of death among older PLHIV with CSVD. Widespread cART use has improved PLHIV life expectancy, but not for PLHIV infected before the cART era, who have not reached the life expectancy of the general population. Hence, older PLHIV are less numerous than the general population worldwide [24] . A similar attenuation of HIV's negative effect with increasing age was observed in prospective studies of stroke in PLHIV [25, 26] . Those authors postulated that age might overshadow the deleterious HIV impact, with traditional vascular risk factors possibly playing a greater role in older PLHIV. In our study, the HIV PAF fell from 56% for PLHIV aged ≤60 years to 4% for those >60 years, whereas PAF values remained unchanged for other risk factors (eg, hypertension). These discrepancies could be explained by differences in study design and/or in the pathophysiology of CSVD, stroke, and coronary heart disease [25] [26] [27] .
As expected from general population data, older age, and hypertension were independently associated with CSVD for PLHIV. However, the CSVD prevalence in the general population has not been well-established for persons <65 years old and, to the best of our knowledge, no consensual estimation exists [2] . For that age group, WMHs were the most frequent CSVD markers, ranging from 20% [28] to 50% [29] and 71% [30] , in line with our estimates (36% overall and 33% for WMHs alone). The variability of those published results may be explained by methodological differences, notably different magnetic field powers and WMH-rating definitions, and risk factor and comorbidity differences [5, 28] . Hypertension's deleterious role is consistently found in CSVD and is a stronger risk factor for small-vessel than large-vessel stroke [31] . Hypertension was also the only modifiable CSVD risk factor identified herein, as elsewhere [1, 2] . We found that PLHIV were not optimally treated for hypertension, underlining the need to reinforce blood pressure control in this setting.
Two specific CSVD risk factors were HIV-related: nadir CD4 <200 cells/µL and the HIV transmission group. Although the CD4 cell count nadir is frequently associated with cerebral large-vessel disease [26, 32] , previous studies reported no association with CSVD [14-16, 18, 19, 32] . The CD4 cell count nadir was a borderline risk factor for CSVD herein, with an aOR of 1.5 (95% CI, 1.0-2.3), despite our large population. In the majority of PLHIV studies, a lower CD4 cell count nadir was a risk factor associated with age-related complications [33] . A higher risk of CSVD among heterosexual men than MSM was observed previously and is probably explained by socioeconomic status differences [32] . Indeed, MSM are better educated and have higher incomes in France, especially in the Paris area [34] . Low incomes are significantly associated with CSVD in the general population [35] .
The main strengths of our study are the recruitment of the largest cohort to date of immunovirologically controlled PLHIV, the exclusion of other potential confounders in order to isolate the HIV impact per se, consistent MRI acquisition and processing parameters with the same high-field scanner, and the same rating conditions for the 2 blinded neuroradiologists. Frequency matching was not completely successful, and PLHIV were 2 years younger than HUCs. Because older age is a major risk factor for CSVD, this 2-year difference could have biased our results toward no difference by HIV status, and therefore cannot explain our findings. Another limitation is the lack of information on socioeconomic status.
Our study results revealed a high CSVD prevalence among middle-aged PLHIV, despite cART-sustained immunovirological control. We confirmed classical risk factors (eg, hypertension and advancing age) and identified a specific HIV-associated factor, the CD4 cell count nadir. Recent study results showing links between CSVD and cognitive and gait impairments, frailty, and stroke in the general population [2, 3, 32] , and PLHIV [16] should prompt medical providers to search for CSVD in PLHIV, using a brief brain MRI. Because the CSVD prevalence among PLHIV >60 years old reached 69% herein, with an aOR of 4.0 relative to the 50-to 54-year age group, screening may also be warranted for this age class [36] .
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